Fundraising Fox

Commodore Capital

Venture capital

New York · Series C–Late Stage · 16 people tracked

Find your way into Commodore Capital

1,756 people in our graph share verified history with the Commodore Capital team — schools, employers, funds. One of them is your warm intro.

Anika Guptaunlockedknows Alexander Muñoz · together at Broad Institute of MIT and Harvard (overlapped)
×4knows the team · via Broad Institute of MIT and Harvard
×3knows the team · via Massachusetts General Hospital
knows the team · via McKinsey & Company
knows the team · via The Wharton School
knows the team · via University of Pennsylvania School of Medicine
Fox Verdict
Sign up to see your fit

Investment thesis

Commodore Capital believes the biopharmaceutical industry is in the early stages of a major innovation cycle, driven by scientific discoveries translating into clinical breakthroughs through novel therapeutic modalities such as genetic medicines and cellular therapies. The firm notes that innovation has shifted from large pharmaceutical companies to smaller biopharmaceutical firms. Commodore aims to be a supportive partner to these companies as they work to bring safe and effective new medicines to patients worldwide.

Source: firm website, verified Sep 1, 2026.

Stage
Series C–Late Stage
HQ
New York, New York, US
Leads rounds
Follows
Instruments
Equity
Founded
2019
Last 12 months
2 investments
AUM
$2.4B
Tracked investments
2

Team · 16 people

from the firm's website & curated & public directories

What they invest in

from 2 of 2 portfolio companies

Biotech ×2Healthtech ×1

HQs:United States×2

Investments · 2 tracked

founders shown can be your intro path
Agenusagenusbio.comNASDAQ: AGENAug 2026

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL.

BiotechHealthtechLexington, US

Garo Armen(Chairman & CEO, Co-founder)Ozer Baysal(Executive Officer)Robert Stein(Executive Officer)Christine Klaskin(Executive Officer)inKaren Valentine(Executive Officer)Steven O'Day(Chief Medical Officer)in

Co-investorsAdvent Life SciencesGrazia Equity GmbHHEALTHCARE ROYALTY PARTNERSOberland CapitalInvusLigand Pharmaceuticals+1 more

Relmada TherapeuticsNASDAQ: RLMDMar 2026

BiotechNew York, US

Sergio Traversa(Executive Officer, Director)Eliseo O. Salinas(President and Chief Scientific Officer)inDouglas Beck(Chief Financial Officer)Charles Casamento(Director)Paul Kelly(Director)Maged Shenouda(Director)

Co-investorsBioAdvanceBAM ElevateBraidwellJanus Henderson InvestorsOrbiMedRA Capital+2 more

Exits · 2

IPOs and acquisitions across the tracked portfolio

AgenusNASDAQ: AGENRelmada TherapeuticsNASDAQ: RLMD

Portfolio news

latest coverage across their companies

Frequently asked questions

What stage does Commodore Capital invest at?
Commodore Capital invests at the Series C, Late Stage stages.
What sectors does Commodore Capital focus on?
Commodore Capital focuses on Biotech.
Where is Commodore Capital located?
Commodore Capital is headquartered in New York, US.
Does Commodore Capital lead rounds?
Commodore Capital typically participates in rounds rather than leading them.

Similar investors

Featured in lists